Compare RMCO & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RMCO | FLNA |
|---|---|---|
| Founded | 2021 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.2M | 30.0M |
| IPO Year | 2021 | 2000 |
| Metric | RMCO | FLNA |
|---|---|---|
| Price | $2.03 | $0.64 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | 9.2K | ★ 462.6K |
| Earning Date | 11-13-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,949,916.00 | ★ $41,119,000.00 |
| Revenue This Year | $61.62 | N/A |
| Revenue Next Year | $62.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 513.30 | N/A |
| 52 Week Low | $1.74 | $0.39 |
| 52 Week High | $5.00 | $2.03 |
| Indicator | RMCO | FLNA |
|---|---|---|
| Relative Strength Index (RSI) | 40.15 | 55.81 |
| Support Level | $1.90 | $0.43 |
| Resistance Level | $2.46 | $0.68 |
| Average True Range (ATR) | 0.14 | 0.06 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 38.00 | 93.03 |
Royalty Management Holding Corp is formed to invest or purchase assets that have near and medium-term income potential to provide RMC with accretive cash flow from which it can reinvest in new assets or expand cash flow from those existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.